C4 Therapeutics, Inc.
CCCC
$1.54
$0.042.67%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 20.51% | 21.81% | 22.87% | 4.01% | -3.37% |
| Total Depreciation and Amortization | -3.30% | -10.30% | -8.56% | -6.94% | 12.17% |
| Total Amortization of Deferred Charges | -- | -100.00% | -92.85% | -67.88% | -43.20% |
| Total Other Non-Cash Items | 1.27% | -8.10% | -1.80% | -10.31% | -17.25% |
| Change in Net Operating Assets | 210.23% | 132.98% | 49.33% | 115.75% | 58.65% |
| Cash from Operations | 39.01% | 36.37% | 28.79% | 18.35% | -0.85% |
| Capital Expenditure | 89.46% | 88.79% | 83.40% | 81.08% | 68.92% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -131.92% | -123.54% | -75.37% | -56.89% | 150.41% |
| Cash from Investing | -132.38% | -124.32% | -74.90% | -55.65% | 171.04% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | 100.00% | -633.33% | -1,466.67% | -- |
| Issuance of Common Stock | -21.80% | 97,719.05% | 29,145.57% | 16,005.24% | 7,329.99% |
| Repurchase of Common Stock | -76.36% | -76.36% | -32.98% | -32.98% | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 3.80% | 2.98% | 35.16% | 37.01% | -0.54% |
| Cash from Financing | -0.34% | 947.86% | 8,087.96% | 475,135.29% | 3,865.91% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -173.29% | -111.50% | 328.73% | 1,062.07% | 309.19% |